申请人:GE HEALTHCARE LIMITED
公开号:US20160214936A1
公开(公告)日:2016-07-28
The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known TSPO-binding radiotracers. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said precursor compound. Other aspects of the invention include a method for the synthesis of the in vivo imaging agent of the invention comprising use of the precursor compound of the invention, a kit for carrying out said method, and a cassette for carrying out an automated version of said method. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.
本发明涉及体内成像,特别是体内成像转位蛋白(TSPO,曾被称为外周苯二氮平受体)。提供了一种基于吲哚的体内成像试剂,克服了与已知的TSPO结合放射性示踪剂相关的问题。本发明还提供了一种前体化合物,可用于合成本发明的体内成像试剂,以及合成所述前体化合物的方法。本发明的其他方面包括一种使用本发明的前体化合物合成本发明的体内成像试剂的方法,用于执行该方法的工具包,以及用于执行该方法的自动化版本的盒式装置。此外,本发明还提供了一种包含本发明的体内成像试剂的放射性药物组合物,以及使用所述体内成像试剂的方法。